Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
625.18B
Market cap625.18B
Price-Earnings ratio
38.50
Price-Earnings ratio38.50
Dividend yield
2.08%
Dividend yield2.08%
Average volume
8.19M
Average volume8.19M
High today
$260.77
High today$260.77
Low today
$255.71
Low today$255.71
Open price
$257.40
Open price$257.40
Volume
7.66M
Volume7.66M
52 Week high
$281.07
52 Week high$281.07
52 Week low
$184.66
52 Week low$184.66

Stock Snapshot

With a market cap of 625.18B, Johnson & Johnson(JNJ) trades at $258.52. The stock has a price-to-earnings ratio of 38.50 and currently yields dividends of 2.08%.

As of 2026-10-21, Johnson & Johnson(JNJ) stock has fluctuated between $255.71 and $260.77. The current price stands at $258.52, placing the stock +1.1% above today's low and -0.9% off the high.

The Johnson & Johnson(JNJ)'s current trading volume is 7.66M, compared to an average daily volume of 8.19M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $281.07 and a 52-week low of $184.66.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $281.07 and a 52-week low of $184.66.

JNJ News

Axios 5h
Head tax rears up again in Mayor Johnson's 2027 budget - Axios

...

Head tax rears up again in Mayor Johnson's 2027 budget - Axios
TipRanks 16h
Johnson & Johnson: Buy Rating Reiterated on Underappreciated Pharma and MedTech Growth, $300 Price Target Unchanged

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Johnson & Johnson and keeping the price target at $300.00. Michael Nedelcovych has given hi...

Simply Wall St 17h
Johnson & Johnson Stock Looks Reasonable As Crohns Drug Data Lands

has delivered a powerful multi year run in its share price, which puts a fresh spotlight on whether the current market value lines up with the cash the business...

Johnson & Johnson Stock Looks Reasonable As Crohns Drug Data Lands

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
22.2%
Sell
7.4%

More JNJ News

Zacks 19h
Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat

Shares of Johnson & Johnson (JNJ Quick QuoteJNJ - Free Report) initially dropped nearly 6% on Oct. 13, after announcing third-quarter 2026 results. Althou...

Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat
TipRanks 20h
Johnson & Johnson announces U.S. launch of Shockwave C2 Aero Fly catheter

Johnson & Johnson announced the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter designed to treat a broad range of calcified coronary artery lesi...

Zacks 20h
The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services

Chicago, IL – October 20, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the l...

The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services
The Wall Street Journal 21h
Health Care Roundup: Market Talk

george frey / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk
24/7 Wall St. 2d
Ds vs. Dividend Stocks: One Protects Your Principal, the Other Could Grow Your Income

Investing Ds vs. Dividend Stocks: One Protects Your Principal, the Other Could Grow Your Income A CD and a dividend stock can both pay you income in retirement,...

Ds vs. Dividend Stocks: One Protects Your Principal, the Other Could Grow Your Income
TipRanks 2d
Johnson & Johnson reports results from Phase 3 FUZION study

Johnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA, or guselkumab, maintained or improved fistula remission through 48 w...

24/7 Wall St. 2d
Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead

Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well ab...

Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.